BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61:677.e1-677.14. [PMID: 19751883 DOI: 10.1016/j.jaad.2009.03.016] [Cited by in Crossref: 111] [Cited by in F6Publishing: 86] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Marsden J, Newton-bishop J, Burrows L, Cook M, Corrie P, Cox N, Gore M, Lorigan P, Mackie R, Nathan P, Peach H, Powell B, Walker C. Revised UK guidelines for the management of cutaneous melanoma 2010. Journal of Plastic, Reconstructive & Aesthetic Surgery 2010;63:1401-19. [DOI: 10.1016/j.bjps.2010.07.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 7.9] [Reference Citation Analysis]
2 Wu YP, Aspinwall LG, Conn BM, Stump T, Grahmann B, Leachman SA. A systematic review of interventions to improve adherence to melanoma preventive behaviors for individuals at elevated risk. Prev Med 2016;88:153-67. [PMID: 27090434 DOI: 10.1016/j.ypmed.2016.04.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
3 Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, Ghiorzo P. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 2017;36:77-90. [PMID: 28283772 DOI: 10.1007/s10555-017-9661-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 12.5] [Reference Citation Analysis]
4 Rossi M, Pellegrini C, Cardelli L, Ciciarelli V, Di Nardo L, Fargnoli MC. Familial Melanoma: Diagnostic and Management Implications. Dermatol Pract Concept 2019;9:10-6. [PMID: 30775140 DOI: 10.5826/dpc.0901a03] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
5 Potrony M, Puig-Butille JA, Farnham JM, Giménez-Xavier P, Badenas C, Tell-Martí G, Aguilera P, Carrera C, Malvehy J, Teerlink CC, Puig S. Genome-wide linkage analysis in Spanish melanoma-prone families identifies a new familial melanoma susceptibility locus at 11q. Eur J Hum Genet 2018;26:1188-93. [PMID: 29706638 DOI: 10.1038/s41431-018-0149-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Villacis RAR, Basso TR, Canto LM, Pinheiro M, Santiago KM, Giacomazzi J, de Paula CAA, Carraro DM, Ashton-Prolla P, Achatz MI, Rogatto SR. Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development. J Mol Med (Berl) 2017;95:523-33. [PMID: 28093616 DOI: 10.1007/s00109-017-1507-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Hansson J. Familial cutaneous melanoma. Adv Exp Med Biol 2010;685:134-45. [PMID: 20687502 DOI: 10.1007/978-1-4419-6448-9_13] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
8 Potjer TP, Helgadottir H, Leenheer M, van der Stoep N, Gruis NA, Höiom V, Olsson H, van Doorn R, Vasen HFA, van Asperen CJ, Dekkers OM, Hes FJ; Dutch Working Group for Clinical Oncogenetics. CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe. J Med Genet 2018;55:661-8. [PMID: 29661971 DOI: 10.1136/jmedgenet-2017-105205] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
9 Abdo JF, Sharma A, Sharma R. Role of Heredity in Melanoma Susceptibility: A Primer for the Practicing Surgeon. Surg Clin North Am 2020;100:13-28. [PMID: 31753108 DOI: 10.1016/j.suc.2019.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Taylor NJ, Mitra N, Qian L, Avril MF, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Gruis NA, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard AL, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Yang XR, Newton-Bishop JA, Kanetsky PA; GenoMEL Study Group. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. J Am Acad Dermatol 2019;81:386-94. [PMID: 30731170 DOI: 10.1016/j.jaad.2019.01.079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Peters MLB, Stobie L, Dudley B, Karloski E, Allen K, Speare V, Dolinsky JS, Tian Y, DeLeonardis K, Krejdovsky J, Button A, Lim C, Borazanci E, Brand R, Tung N. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. Cancer 2019;125:2488-96. [PMID: 30980401 DOI: 10.1002/cncr.32077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Wu YP, Mays D, Kohlmann W, Tercyak KP. Pediatric Predispositional Genetic Risk Communication: Potential Utility for Prevention and Control of Melanoma Risk as an Exemplar. J Genet Couns 2017;26:887-93. [PMID: 28547663 DOI: 10.1007/s10897-017-0105-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Fan M, Pfeffer SR, Lynch HT, Cassidy P, Leachman S, Pfeffer LM, Kopelovich L. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention. Oncotarget 2013;4:128-41. [PMID: 23371019 DOI: 10.18632/oncotarget.786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
14 Ghanem G, Fabrice J. Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. Mol Oncol 2011;5:150-5. [PMID: 21324755 DOI: 10.1016/j.molonc.2011.01.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
15 McWilliams RR, Wieben ED, Rabe KG, Pedersen KS, Wu Y, Sicotte H, Petersen GM. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2011;19:472-478. [PMID: 21150883 DOI: 10.1038/ejhg.2010.198] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 6.7] [Reference Citation Analysis]
16 de Torre C, Garcia-Casado Z, Martínez-Escribano JA, Botella-Estrada R, Bañuls J, Oliver V, Mercader P, Azaña JM, Frias J, Nagore E. Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain. Melanoma Res 2010;20:342-8. [PMID: 20539244 DOI: 10.1097/CMR.0b013e32833b159d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 McMeniman EK, Peach E, Lee KJ, Yanes T, Jagirdar K, Stark MS, Soyer HP, Duffy DL, McInerney-Leo AM, Sturm RA. CDKN2A testing threshold in a high-risk Australian melanoma cohort: number of primaries, family history and young age of onset impact risk. J Eur Acad Dermatol Venereol 2020;34:e797-8. [PMID: 32386439 DOI: 10.1111/jdv.16627] [Reference Citation Analysis]
18 Palmieri G, Colombino M, Casula M, Budroni M, Manca A, Sini MC, Lissia A, Stanganelli I, Ascierto PA, Cossu A. Epidemiological and genetic factors underlying melanoma development in Italy. Melanoma Manag 2015;2:149-63. [PMID: 30190844 DOI: 10.2217/mmt.15.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Gerstenblith MR, Goldstein AM, Tucker MA. Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am 2010;24:885-906. [PMID: 20816579 DOI: 10.1016/j.hoc.2010.06.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
20 Grazziotin TC, Rey MC, Bica CG, Pinto LA, Bonamigo RR, Puig-Butille JA, Cuellar F, Puig S. Genetic variations of patients with familial or multiple melanoma in Southern Brazil. J Eur Acad Dermatol Venereol 2013;27:e179-85. [PMID: 22621339 DOI: 10.1111/j.1468-3083.2012.04567.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Arron ST, Raymond AK, Yanik EL, Castenson D, McCulloch CE, Clarke CA, Paddock LE, Niu X, Engels EA. Melanoma Outcomes in Transplant Recipients With Pretransplant Melanoma. Dermatol Surg 2016;42:157-66. [PMID: 26818209 DOI: 10.1097/DSS.0000000000000602] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Yu WY, Hill ST, Chan ER, Pink JJ, Cooper K, Leachman S, Lund AW, Kulkarni R, Bordeaux JS. Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma. J Invest Dermatol 2021;141:1802-9. [PMID: 33417917 DOI: 10.1016/j.jid.2020.12.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Bergman W, Gruis NA. Management of melanoma families. Cancers (Basel) 2010;2:549-66. [PMID: 24281082 DOI: 10.3390/cancers2020549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol 2016;74:395-407; quiz 408-10. [PMID: 26892650 DOI: 10.1016/j.jaad.2015.08.038] [Cited by in Crossref: 98] [Cited by in F6Publishing: 67] [Article Influence: 19.6] [Reference Citation Analysis]
25 Udayakumar D, Mahato B, Gabree M, Tsao H. Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg 2010;29:190-5. [PMID: 21051013 DOI: 10.1016/j.sder.2010.06.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
26 Visser M, van der Stoep N, Gruis N. Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013-2018). Fam Cancer 2019;18:267-71. [PMID: 30659395 DOI: 10.1007/s10689-018-00115-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol 2014;37:635-41. [PMID: 23563206 DOI: 10.1097/COC.0b013e3182868e82] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
28 Müller C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, Sunder-Plassmann R, Scheurecker C, Richtig E, Fae I, Fischer G, Pehamberger H, Okamoto I. Characterization of patients at high risk of melanoma in Austria. Br J Dermatol 2016;174:1308-17. [PMID: 26800492 DOI: 10.1111/bjd.14407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
29 Aguilera P, Malvehy J, Carrera C, Palou J, Puig-Butillé JA, Alòs L, Badenas C, Puig S. Clinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain. J Clin Exp Dermatol Res 2014;5:231. [PMID: 25893138 DOI: 10.4172/2155-9554.1000231] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
30 Reyes MA, Eisen DB. Inherited syndromes: Inherited syndromes. Dermatologic Therapy 2010;23:606-42. [DOI: 10.1111/j.1529-8019.2010.01368.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 De Mozzi P, Alexandroff A, Johnston G. Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.: Updates from the BAD 91st Annual Meeting, 2011. British Journal of Dermatology 2012;167:232-9. [DOI: 10.1111/j.1365-2133.2012.11080.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Zocchi L, Lontano A, Merli M, Dika E, Nagore E, Quaglino P, Puig S, Ribero S. Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management. J Clin Med 2021;10:3760. [PMID: 34442055 DOI: 10.3390/jcm10163760] [Reference Citation Analysis]
33 Christodoulou E, van Doorn R, Visser M, Teunisse A, Versluis M, van der Velden P, Hayward NK, Jochemsen A, Gruis N. NEK11 as a candidate high-penetrance melanoma susceptibility gene. J Med Genet 2020;57:203-10. [PMID: 31704778 DOI: 10.1136/jmedgenet-2019-106134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Mangas C, Potrony M, Mainetti C, Bianchi E, Carrozza Merlani P, Mancarella Eberhardt A, Maspoli-Postizzi E, Marazza G, Marcollo-Pini A, Pelloni F, Sessa C, Simona B, Puig-Butillé JA, Badenas C, Puig S. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF. Br J Dermatol 2016;175:1030-7. [PMID: 27473757 DOI: 10.1111/bjd.14897] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
35 Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining the patient at high risk for melanoma. Int J Dermatol 2010;49:362-76. [PMID: 20465687 DOI: 10.1111/j.1365-4632.2010.04381.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
36 Taber JM, Aspinwall LG, Drummond DM, Stump TK, Kohlmann W, Champine M, Cassidy P, Leachman SA. Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma. Ann Behav Med 2021;55:24-40. [PMID: 32415830 DOI: 10.1093/abm/kaaa028] [Reference Citation Analysis]
37 Puig S, Potrony M, Cuellar F, Puig-Butille JA, Carrera C, Aguilera P, Nagore E, Garcia-Casado Z, Requena C, Kumar R, Landman G, Costa Soares de Sá B, Gargantini Rezze G, Facure L, de Avila AL, Achatz MI, Carraro DM, Duprat Neto JP, Grazziotin TC, Bonamigo RR, Rey MC, Balestrini C, Morales E, Molgo M, Bakos RM, Ashton-Prolla P, Giugliani R, Larre Borges A, Barquet V, Pérez J, Martínez M, Cabo H, Cohen Sabban E, Latorre C, Carlos-Ortega B, Salas-Alanis JC, Gonzalez R, Olazaran Z, Malvehy J, Badenas C. Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. Genet Med 2016;18:727-36. [PMID: 26681309 DOI: 10.1038/gim.2015.160] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
38 Gabree M, Seidel M. Genetic testing by cancer site: skin. Cancer J 2012;18:372-80. [PMID: 22846740 DOI: 10.1097/PPO.0b013e3182624664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Wansleben S, Peres J, Hare S, Goding CR, Prince S. T-box transcription factors in cancer biology. Biochim Biophys Acta 2014;1846:380-91. [PMID: 25149433 DOI: 10.1016/j.bbcan.2014.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
40 Fried L, Tan A, Bajaj S, Liebman TN, Polsky D, Stein JA. Technological advances for the detection of melanoma: Advances in molecular techniques. J Am Acad Dermatol 2020;83:996-1004. [PMID: 32360759 DOI: 10.1016/j.jaad.2020.03.122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
41 Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019;80:208-50. [PMID: 30392755 DOI: 10.1016/j.jaad.2018.08.055] [Cited by in Crossref: 169] [Cited by in F6Publishing: 126] [Article Influence: 56.3] [Reference Citation Analysis]
42 Fogel AL, Sarin KY, Teng JM. Genetic diseases associated with an increased risk of skin cancer development in childhood. Current Opinion in Pediatrics 2017;29:426-33. [DOI: 10.1097/mop.0000000000000514] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
43 Aspinwall LG, Stump TK, Taber JM, Drummond DM, Kohlmann W, Champine M, Leachman SA. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk. Transl Behav Med 2018;8:29-43. [PMID: 29385581 DOI: 10.1093/tbm/ibx011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
44 Potrony M, Puig-Butillé JA, Aguilera P, Badenas C, Carrera C, Malvehy J, Puig S. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol 2014;71:888-95. [PMID: 25064638 DOI: 10.1016/j.jaad.2014.06.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
45 Argenziano G, Brancaccio G, Moscarella E, Dika E, Fargnoli MC, Ferrara G, Longo C, Pellacani G, Peris K, Pimpinelli N, Quaglino P, Rongioletti F, Simonacci M, Zalaudek I, Calzavara Pinton P. Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. G Ital Dermatol Venereol 2020;155:126-45. [PMID: 32394673 DOI: 10.23736/S0392-0488.19.06383-1] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
46 Miller PJ, Duraisamy S, Newell JA, Chan PA, Tie MM, Rogers AE, Ankuda CK, von Walstrom GM, Bond JP, Greenblatt MS. Classifying variants of CDKN2A using computational and laboratory studies. Hum Mutat 2011;32:900-11. [PMID: 21462282 DOI: 10.1002/humu.21504] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
47 Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-62; quiz 263. [PMID: 25645574 DOI: 10.1038/ajg.2014.435] [Cited by in Crossref: 735] [Cited by in F6Publishing: 548] [Article Influence: 122.5] [Reference Citation Analysis]
48 Marsden J, Newton-bishop J, Burrows L, Cook M, Corrie P, Cox N, Gore M, Lorigan P, Mackie R, Nathan P, Peach H, Powell B, Walker C. Revised U.K. guidelines for the management of cutaneous melanoma 2010: Guidelines for management of cutaneous melanoma 2010. British Journal of Dermatology 2010;163:238-56. [DOI: 10.1111/j.1365-2133.2010.09883.x] [Cited by in Crossref: 245] [Cited by in F6Publishing: 201] [Article Influence: 22.3] [Reference Citation Analysis]
49 Chan SH, Chiang J, Ngeow J. CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition. Hered Cancer Clin Pract 2021;19:21. [PMID: 33766116 DOI: 10.1186/s13053-021-00178-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Aspinwall LG, Taber JM, Kohlmann W, Leaf SL, Leachman SA. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. Genet Med 2014;16:846-53. [PMID: 24763292 DOI: 10.1038/gim.2014.37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
51 Abdullah C, Wang X, Becker D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle 2011;10:977-88. [PMID: 21358262 DOI: 10.4161/cc.10.6.15079] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
52 Sargen MR, Kanetsky PA, Newton-Bishop J, Hayward NK, Mann GJ, Gruis NA, Tucker MA, Goldstein AM, Bianchi-Scarra G, Puig S, Elder DE. Histologic features of melanoma associated with CDKN2A genotype. J Am Acad Dermatol 2015;72:496-507.e7. [PMID: 25592620 DOI: 10.1016/j.jaad.2014.11.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
53 Martín-algarra S, Fernández-figueras MT, López-martín JA, Santos-briz A, Arance A, Lozano MD, Berrocal A, Ríos-martín JJ, Espinosa E, Rodríguez-peralto JL. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2014;16:362-73. [DOI: 10.1007/s12094-013-1090-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 La Starza R, Pierini T, Pastorino L, Albi E, Matteucci C, Crescenzi B, Sportoletti P, Covarelli P, Falzetti F, Roti G, Ascani S, Mecucci C. Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin. Mol Cytogenet 2018;11:6. [PMID: 29371889 DOI: 10.1186/s13039-017-0353-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 De Unamuno B, García-Casado Z, Bañuls J, Requena C, Lopez-Guerrero JA, Nagore E. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer. Melanoma Res 2018;28:246-9. [PMID: 29543703 DOI: 10.1097/CMR.0000000000000442] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
56 Fidalgo F, Rodrigues TC, Silva AG, Facure L, de Sá BC, Duprat JP, Achatz MI, Rosenberg C, Carraro DM, Krepischi AC. Role of rare germline copy number variation in melanoma-prone patients. Future Oncol 2016;12:1345-57. [PMID: 27020340 DOI: 10.2217/fon.16.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Glanz K, Volpicelli K, Kanetsky PA, Ming ME, Schuchter LM, Jepson C, Domchek SM, Armstrong K. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev 2013;22:607-14. [PMID: 23392000 DOI: 10.1158/1055-9965.EPI-12-1174] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
58 Badenas C, Aguilera P, Puig-Butillé JA, Carrera C, Malvehy J, Puig S. Genetic counseling in melanoma. Dermatol Ther 2012;25:397-402. [PMID: 23046018 DOI: 10.1111/j.1529-8019.2012.01499.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
59 Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S. Update in genetic susceptibility in melanoma. Ann Transl Med 2015;3:210. [PMID: 26488006 DOI: 10.3978/j.issn.2305-5839.2015.08.11] [Cited by in F6Publishing: 50] [Reference Citation Analysis]
60 Grander LC, Cabral F, Lisboa AP, Vale G, Barcaui CB, Maceira JM. Multiple cutaneous melanomas associated with gastric and brain metastases. An Bras Dermatol 2016;91:98-100. [PMID: 28300909 DOI: 10.1590/abd1806-4841.20164374] [Reference Citation Analysis]
61 Ward WH, Lambreton F, Goel N, Yu JQ, Farma JM; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, PA, USA, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Clinical Presentation and Staging of Melanoma. In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy. Codon Publications; 2017. pp. 79-89. [DOI: 10.15586/codon.cutaneousmelanoma.2017.ch6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Sá BCS, Moredo LF, Gomes EE, Araújo ESS, Duprat JP. Hereditary melanoma: a five-year study of Brazilian patients in a cancer referral center - phenotypic characteristics of probands and pathological features of primary tumors. An Bras Dermatol 2018;93:337-40. [PMID: 29924249 DOI: 10.1590/abd1806-4841.20186201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Borroni RG, Manganoni AM, Grassi S, Grasso M, Diegoli M, Giorgianni C, Favalli V, Pavoni L, Cespa M, Arbustini E. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy. Melanoma Res 2017;27:97-103. [PMID: 28060055 DOI: 10.1097/CMR.0000000000000324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Harland M, Cust AE, Badenas C, Chang YM, Holland EA, Aguilera P, Aitken JF, Armstrong BK, Barrett JH, Carrera C, Chan M, Gascoyne J, Giles GG, Agha-Hamilton C, Hopper JL, Jenkins MA, Kanetsky PA, Kefford RF, Kolm I, Lowery J, Malvehy J, Ogbah Z, Puig-Butille JA, Orihuela-Segalés J, Randerson-Moor JA, Schmid H, Taylor CF, Whitaker L, Bishop DT, Mann GJ, Newton-Bishop JA, Puig S. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered Cancer Clin Pract 2014;12:20. [PMID: 25780468 DOI: 10.1186/1897-4287-12-20] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
65 Ransohoff KJ, Jaju PD, Tang JY, Carbone M, Leachman S, Sarin KY. Familial skin cancer syndromes: Increased melanoma risk. J Am Acad Dermatol 2016;74:423-34; quiz 435-6. [PMID: 26892652 DOI: 10.1016/j.jaad.2015.09.070] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
66 Wu YP, Aspinwall LG, Michaelis TC, Stump T, Kohlmann WG, Leachman SA. Discussion of photoprotection, screening, and risk behaviors with children and grandchildren after melanoma genetic testing. J Community Genet 2016;7:21-31. [PMID: 26099287 DOI: 10.1007/s12687-015-0243-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
67 Potrony M, Puig-Butille JA, Ribera-Sola M, Iyer V, Robles-Espinoza CD, Aguilera P, Carrera C, Malvehy J, Badenas C, Landi MT, Adams DJ, Puig S. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. Br J Dermatol 2019;181:105-13. [PMID: 30451293 DOI: 10.1111/bjd.17443] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
68 Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. J Am Acad Dermatol 2016;74:325-32. [PMID: 26775776 DOI: 10.1016/j.jaad.2015.09.053] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
69 Aspinwall LG, Taber JM, Kohlmann W, Leaf SL, Leachman SA. Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall. J Genet Couns 2014;23:421-37. [PMID: 24322567 DOI: 10.1007/s10897-013-9676-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
70 Gabree M, Patel D, Rodgers L. Clinical Applications of Melanoma Genetics. Curr Treat Options in Oncol 2014;15:336-50. [DOI: 10.1007/s11864-014-0282-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Hawkes JE, Campbell J, Garvin D, Cannon-Albright L, Cassidy P, Leachman SA. Lack of GNAQ and GNA11 Germ-Line Mutations in Familial Melanoma Pedigrees with Uveal Melanoma or Blue Nevi. Front Oncol 2013;3:160. [PMID: 23825798 DOI: 10.3389/fonc.2013.00160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
72 Brand R, Borazanci E, Speare V, Dudley B, Karloski E, Peters MLB, Stobie L, Bahary N, Zeh H, Zureikat A, Hogg M, Lee K, Tsung A, Rhee J, Ohr J, Sun W, Lee J, Moser AJ, DeLeonardis K, Krejdovsky J, Dalton E, LaDuca H, Dolinsky J, Colvin A, Lim C, Black MH, Tung N. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer 2018;124:3520-7. [PMID: 30067863 DOI: 10.1002/cncr.31628] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
73 Di Lorenzo S, Fanale D, Corradino B, Caló V, Rinaldi G, Bazan V, Giordano A, Cordova A, Russo A. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature? Cancer Biol Ther 2016;17:83-90. [PMID: 26650572 DOI: 10.1080/15384047.2015.1108494] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
74 Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag 2017;4:13-37. [PMID: 28758010 DOI: 10.2217/mmt-2016-0022] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 14.5] [Reference Citation Analysis]
75 Taber JM, Aspinwall LG, Kohlmann W, Dow R, Leachman SA. Parental preferences for CDKN2A/p16 testing of minors. Genet Med 2010;12:823-38. [PMID: 21045708 DOI: 10.1097/GIM.0b013e3181f87278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
76 Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV. Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer 2018;18:697. [PMID: 29945567 DOI: 10.1186/s12885-018-4573-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
77 Dalmasso B, Pastorino L, Ciccarese G, Andreotti V, Grillo F, Mastracci L, Spagnolo F, Ballestrero A, Queirolo P, Bruno W, Ghiorzo P. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. J Am Acad Dermatol 2019;80:1263-71. [PMID: 30274933 DOI: 10.1016/j.jaad.2018.07.060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
78 Ghiorzo P. Genetic predisposition to pancreatic cancer. World J Gastroenterol 2014; 20(31): 10778-10789 [PMID: 25152581 DOI: 10.3748/wjg.v20.i31.10778] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
79 Marzuka-Alcalá A, Gabree MJ, Tsao H. Melanoma susceptibility genes and risk assessment. Methods Mol Biol 2014;1102:381-93. [PMID: 24258989 DOI: 10.1007/978-1-62703-727-3_20] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
80 Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, Dalle S, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita L, Martin L, Crickx B, Joly P, Thomas L, Bressac-de Paillerets B, Avril MF, Demenais F; French Familial Melanoma Study Group. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol 2012;67:1257-64. [PMID: 22841127 DOI: 10.1016/j.jaad.2012.05.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
81 Hegde UP, Grant-kels JM. Ethical issues in cutaneous melanoma. Clinics in Dermatology 2012;30:501-10. [DOI: 10.1016/j.clindermatol.2011.06.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Gironi LC, Colombo E, Farinelli P, Giorgione R, Bozzola C, Ogliara P, Pasini B. Germline CDKN2A mutations in childhood melanoma: a case of melanoma-pancreatic cancer syndrome. Int J Dermatol 2015;54:e553-5. [PMID: 26381259 DOI: 10.1111/ijd.12933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Sargen MR, Merrill SL, Chu EY, Nathanson KL. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. Br J Dermatol 2016;175:785-9. [PMID: 26876133 DOI: 10.1111/bjd.14485] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
84 De Torre C, Martínez-escribano J. Novel CDKN2A mutation detected in Spanish melanoma pedigree: Letter to the Editor. Experimental Dermatology 2010;19:e333-5. [DOI: 10.1111/j.1600-0625.2009.01048.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
85 Helgadottir H, Tuominen R, Olsson H, Hansson J, Höiom V. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. J Am Acad Dermatol 2017;77:893-901. [PMID: 28818438 DOI: 10.1016/j.jaad.2017.05.050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
86 Bruno W, Martinuzzi C, Dalmasso B, Andreotti V, Pastorino L, Cabiddu F, Gualco M, Spagnolo F, Ballestrero A, Queirolo P, Grillo F, Mastracci L, Ghiorzo P. Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations. Oncotarget 2018;9:5691-702. [PMID: 29464027 DOI: 10.18632/oncotarget.23204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]